Clinical and laboratory features of patients with CAEBV
| . | Patient . | |||
|---|---|---|---|---|
| CAEBV1 . | CAEBV2 . | CAEBV3 . | CAEBV4 . | |
| Age, y/sex | 2/F | 5/F | 46/F | 3/M |
| Duration of active disease (y) | 2 | 5+ | 3 | 10 |
| Hepatosplenomegaly (cm) | 8/10 | −/− | 6/3 | 2/− |
| Lymphoadenopathy | + | − | − | − |
| Skin manifestations | + | + | − | + |
| Hypersensitivity to mosquito bite | − | − | − | + |
| TCR rearrangement | + | − | + | − |
| EBV terminal repeat | Mono | Mono | Mono | NT |
| Malignant transformation | + | − | + | − |
| Anti-EBV antibody titer to | ||||
| VCA-IgG | 20 480 | 2 560 | 2 560 | 640 |
| VCA-IgM | < 10 | < 10 | NT | < 10 |
| EA-DR IgG | 10 240 | 640 | 2 560 | 10 |
| EBNA | 160 | 80 | 10 | 10 |
| Therapy | Chemotherapy, BMT | None | Steroids | Steroids |
| Activated T-cell infusion | Chemotherapy | VCR | ||
| Outcome | Alive | Alive | Deceased | Alive |
| . | Patient . | |||
|---|---|---|---|---|
| CAEBV1 . | CAEBV2 . | CAEBV3 . | CAEBV4 . | |
| Age, y/sex | 2/F | 5/F | 46/F | 3/M |
| Duration of active disease (y) | 2 | 5+ | 3 | 10 |
| Hepatosplenomegaly (cm) | 8/10 | −/− | 6/3 | 2/− |
| Lymphoadenopathy | + | − | − | − |
| Skin manifestations | + | + | − | + |
| Hypersensitivity to mosquito bite | − | − | − | + |
| TCR rearrangement | + | − | + | − |
| EBV terminal repeat | Mono | Mono | Mono | NT |
| Malignant transformation | + | − | + | − |
| Anti-EBV antibody titer to | ||||
| VCA-IgG | 20 480 | 2 560 | 2 560 | 640 |
| VCA-IgM | < 10 | < 10 | NT | < 10 |
| EA-DR IgG | 10 240 | 640 | 2 560 | 10 |
| EBNA | 160 | 80 | 10 | 10 |
| Therapy | Chemotherapy, BMT | None | Steroids | Steroids |
| Activated T-cell infusion | Chemotherapy | VCR | ||
| Outcome | Alive | Alive | Deceased | Alive |
TCR indicates T-cell receptor; Mono, monoclonal; NT, not tested; BMT, bone marrow transplantation; VCR, vincristine, for other abbreviations, see Table 1.